Andrew John Partridge net worth and biography

Andrew Partridge Biography and Net Worth

Chief Growth Officer of GRAIL

Andy Partridge is Chief Growth Officer at GRAIL. He brings more than 25 years of global sales and marketing experience leading global commercial launches across multiple indications, including oncology, hematology and rare diseases. Prior to joining GRAIL, he served as Chief Commercial Officer at Turning Point Therapeutics, building out the commercial team for the launches of oral oncology agents for rare lung cancer mutations. As Senior Vice President and Head of North American Commercial Operations at Vertex Pharmaceuticals, he built the team to successfully launch multiple cystic fibrosis therapies and new indications, creating a multi-billion dollar franchise and transforming patients’ lives. He also served in sales and marketing roles at Schering-Plough, Roche, and Amgen. Andy started his business career in a sales role for Boehringer-Mannheim Diagnostics after earning a Higher National Diploma in Medical Laboratory Sciences from Birmingham City University in the U.K. and working as a Medical Laboratory Scientist in a busy city center academic hospital.

What is Andrew John Partridge's net worth?: The estimated net worth of Andrew John Partridge is at least $10.07 million as of June 4th, 2026. Mr. Partridge owns 163,738 shares of GRAIL stock worth more than $10,072,998 as of June 8th. This net worth approximation does not reflect any other assets that Mr. Partridge may own. Learn More about Andrew John Partridge's net worth.
How do I contact Andrew John Partridge?: The corporate mailing address for Mr. Partridge and other GRAIL executives is 1525 O'brien DRIVE, MENLO PARK, CA, 94025. GRAIL can also be reached via phone at (650) 771-9796 and via email at [email protected]. Learn More on Andrew John Partridge's contact information.
Has Andrew John Partridge been buying or selling shares of GRAIL?: Over the course of the past ninety days, Andrew John Partridge has sold $91,070.28 in shares of GRAIL stock. Most recently, Andrew John Partridge sold 1,491 shares of the business's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a transaction totalling $91,070.28. Following the completion of the sale, the insider now directly owns 163,738 shares of the company's stock, valued at $10,001,117.04. Learn More on Andrew John Partridge's trading history.
Who are GRAIL's active insiders?: GRAIL's insider roster includes Aaron Freidin (CFO), Joshua Ofman (President), Andrew Partridge (Chief Growth Officer), and Robert Ragusa (CEO). Learn More on GRAIL's active insiders.
Are insiders buying or selling shares of GRAIL?: During the last year, insiders at the sold shares 22 times. They sold a total of 786,747 shares worth more than $40,737,620.15. The most recent insider tranaction occured on June, 4th when insider Andrew John Partridge sold 1,491 shares worth more than $91,070.28. Insiders at GRAIL own 1.8% of the company. Learn More about insider trades at GRAIL.
Information on this page was last updated on 6/4/2026.

Andrew John Partridge Insider Trading History at GRAIL

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/4/2026	Sell	1,491	$61.08	$91,070.28	163,738

Andrew John Partridge Buying and Selling Activity at GRAIL

GRAIL Company Overview

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Today's Range

Now: $61.31

$58.56

$61.99

50 Day Range

MA: $57.27

$45.63

$73.92

2 Week Range

Now: $61.31

$29.95

$118.84

Volume

480,122 shs

Average Volume

1,063,901 shs

Market Capitalization

$2.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.15